Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 25.1% in January
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 25.1% in January
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 5,590,000 shares, a growth of 25.1% from the December 31st total of 4,470,000 shares. Approximately 14.0% of the company's stock are sold short. Based on an average trading volume of 533,200 shares, the short-interest ratio is presently 10.5 days.
第一天生物制药公司(纳斯达克：曙光评级)看到空头股数在一月份有很大的增长。截至1月15日，空头股数共有559万股，比12月31日的447万股增长了25.1%。该公司约14.0%的股票被卖空。以平均成交量53.32万股计算，目前短息比率为10.5天。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
DAWN has been the topic of a number of research reports. Bank of America initiated coverage on Day One Biopharmaceuticals in a research report on Thursday, December 1st. They set a "buy" rating and a $34.00 target price on the stock. Piper Sandler upped their price objective on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Sunday, January 8th. HC Wainwright raised their price objective on shares of Day One Biopharmaceuticals from $35.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, January 9th. The Goldman Sachs Group boosted their target price on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the stock a "buy" rating in a research report on Monday, January 9th. Finally, Needham & Company LLC assumed coverage on shares of Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They issued a "buy" rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $43.50.
黎明已经成为许多研究报告的主题。美国银行在12月1日星期四的一份研究报告中开始了对第一天生物制药的保险。他们为该股设定了“买入”评级和34.00美元的目标价。派珀·桑德勒在1月8日周日的一份报告中将第一天生物制药公司的股票目标价从40.00美元上调至45.00美元，并给予该股“增持”评级。1月9日，周一，HC Wainwright在一份研究报告中将第一天生物制药公司的股票目标价从35.00美元上调至45.00美元，并给予该公司“买入”评级。1月9日，高盛夫妇在一份研究报告中将第一天生物制药的目标价从45.00美元上调至62.00美元，并给予该股“买入”评级。最后，Needham&Company LLC在12月14日星期三的一份研究报告中对第一天生物制药公司的股票进行了报道。他们对该股给予了“买入”评级和40.00美元的目标价。根据MarketBeat.com的数据，六位投资分析师对该股的评级为买入，目前该股的普遍评级为买入，平均目标价为43.50美元。
Day One Biopharmaceuticals Price Performance
首日生物药品价格表现
NASDAQ:DAWN traded down $0.09 during trading hours on Friday, hitting $21.45. 263,007 shares of the company traded hands, compared to its average volume of 641,030. Day One Biopharmaceuticals has a one year low of $5.44 and a one year high of $28.35. The firm's 50-day simple moving average is $21.31 and its 200-day simple moving average is $21.15.
纳斯达克：曙光在周五的交易时间里下跌了0.09美元，达到21.45美元。该公司有263,007股易手，而其平均成交量为641,030股。第一天生物制药的一年低点为5.44美元，一年高位为28.35美元。该公司的50日简单移动均线切入位为21.31美元，200日简单移动均线切入位为21.15美元。
Insider Activity at Day One Biopharmaceuticals
生物制药公司上市第一天的内部活动
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total value of $228,600.00. Following the completion of the sale, the insider now directly owns 1,250,148 shares in the company, valued at $28,578,383.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total transaction of $228,600.00. Following the transaction, the insider now owns 1,250,148 shares of the company's stock, valued at approximately $28,578,383.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie Papanek Grant sold 5,000 shares of the firm's stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $20.04, for a total value of $100,200.00. Following the completion of the sale, the director now owns 424,358 shares of the company's stock, valued at $8,504,134.32. The disclosure for this sale can be found here. Insiders have sold 151,678 shares of company stock worth $3,189,287 in the last quarter. Company insiders own 8.70% of the company's stock.
在第一天的其他生物制药新闻中，内部人士塞缪尔·C·布莱克曼在1月10日星期二的一笔交易中出售了10,000股该公司的股票。这些股票的平均价格为22.86美元，总价值为228,600.00美元。出售完成后，这位内部人士现在直接拥有该公司1,250,148股，价值28,578,383.28美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在美国证券交易委员会网站。在其他新闻方面，内部人士塞缪尔·C·布莱克曼在1月10日星期二的交易中出售了10,000股该股。这些股票以22.86美元的平均价格出售，总成交金额为228,600.00美元。交易完成后，这位内部人士现在拥有1,250,148股该公司股票，价值约28,578,383.28美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过美国证券交易委员会网站。此外，董事朱莉·帕帕内克·格兰特在一笔日期为11月1日星期二的交易中出售了5,000股该公司股票。这些股票的平均价格为20.04美元，总价值为100,200.00美元。出售完成后，董事现在拥有424,358股该公司的股票，价值8,504,134.32美元。关于这次销售的披露可以找到这里。上个季度，内部人士出售了151,678股公司股票，价值3,189,287美元。公司内部人士持有该公司8.70%的股份。
Hedge Funds Weigh In On Day One Biopharmaceuticals
对冲基金在生物制药上市首日发表意见
Hedge funds have recently modified their holdings of the company. Atlas Venture Life Science Advisors LLC increased its position in shares of Day One Biopharmaceuticals by 9.3% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company's stock valued at $160,533,000 after acquiring an additional 766,667 shares during the last quarter. FMR LLC increased its position in shares of Day One Biopharmaceuticals by 163.1% during the 2nd quarter. FMR LLC now owns 6,826,574 shares of the company's stock valued at $122,196,000 after purchasing an additional 4,232,055 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Day One Biopharmaceuticals by 68.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company's stock worth $62,867,000 after purchasing an additional 1,425,674 shares during the period. BlackRock Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 29.5% in the 3rd quarter. BlackRock Inc. now owns 2,541,235 shares of the company's stock worth $50,901,000 after buying an additional 578,511 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in Day One Biopharmaceuticals by 59.8% during the second quarter. Franklin Resources Inc. now owns 2,465,380 shares of the company's stock valued at $44,130,000 after buying an additional 922,521 shares during the period. Institutional investors own 86.08% of the company's stock.
对冲基金最近调整了对该公司的持股。Atlas Venture Life Science Advisors LLC在第二季度将其在第一天生物制药公司的股票头寸增加了9.3%。Atlas Venture Life Science Advisors LLC在上个季度增持了766,667股后，现在拥有该公司8,968,305股股票，价值160,533,000美元。FMR LLC在第二季度将其在第一天生物制药公司的股票头寸增加了163.1%。FMR LLC在上个季度额外购买了4,232,055股后，现在拥有6,826,574股该公司股票，价值122,196,000美元。Deerfield Management Company L.P.Series C在第二季度将其在第一天生物制药公司的股份增加了68.3%。Deerfield Management Company L.P.C系列现在拥有该公司3,512,123股股票，价值62,867,000美元，在此期间又购买了1,425,674股。贝莱德股份有限公司在第三季度增持了第一天生物制药公司的股票29.5%。贝莱德股份有限公司在上季度增持了578,511股后，目前持有该公司2,541,235股股票，价值50,901,000美元。最后，富兰克林资源公司在第二季度将其在第一天生物制药公司的头寸增加了59.8%。富兰克林资源公司目前持有该公司2,465,380股股票，价值44,130,000美元，在此期间又购买了922,521股。机构投资者持有该公司86.08%的股票。
Day One Biopharmaceuticals Company Profile
第一天生物制药公司简介
(Get Rating)
(获取评级)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
第一天生物制药公司是一家临床阶段的生物制药公司，为基因定义的癌症患者开发和商业化靶向疗法。它的主要候选产品是DAY101，这是一种口服II型泛快速加速纤维肉瘤激酶抑制剂，目前正处于儿童复发/进展性低级别胶质瘤患者的II期临床试验中。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 在第一天生物制药(黎明)获得一份免费的StockNews.com研究报告
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物制药日报》第一天的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对第一天生物制药和相关公司的最新新闻和分析师评级的每日简要摘要。